The Study of Apelin-13 for the Assessment of Endothelial Dysfunction in Prehypertension and Hypertension Patients

Document Type : Original Article


1 Department of Biochemistry, Siddhartha Medical College, Andhra Pradesh, India

2 Department of Biochemistry, Nimra Institute of Medical Sciences, Andhra Pradesh, India


Background and aim: Hypertension is a leading global burden of deaths, coronary heart diseases, and stroke. Hypertension causes low-grade chronic systemic inflammation associated with endothelial dysfunction and vascular complications. The present study aimed to assess Apelin-13 levels in prehypertension and hypertension patients and find their association with oxidized low-density lipoprotein (LDL) and lipid profile.
Material and methods: Sixty prehypertension and 60 hypertension with the age group of 35 to 50 years were selected, and 60 healthy age-matched subjects were selected as controls. Beckman Colter's fully automated analyzer carried out serum apelin-13 and oxidized LDL estimated by enzyme-linked immunosorbent assay (ELISA) and other routine investigations.
Results: Apelin-13 levels were significantly increased in hypertensive patients compared to prehypertensive patients. A significant positive correlation was observed between apelin-13 and oxidized LDL and triglyceride levels. Further, there was no significance observed between other lipid profile parameters.
Conclusions: Apelin-13 is a vital factor for assessing endothelial dysfunction in hypertensive patients. Reduction of apelin-13 may be beneficial in preventing vascular complications and coronary heart diseases in hypertensive patients.


Main Subjects

[1] Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European heart journal. 2018;39(33):3021-104.
[2] Sigmund CD, Carey RM, Appel LJ, Arnett DK, Bosworth HB, Cushman WC, et al. Report of the national heart, lung, and blood institute working group on hypertension: Barriers to translation. Hypertension. 2020;75(4):902-17.
[3] Monzo L, Ferreira JP, Lamiral Z, Bozec E, Boivin JM, Huttin O, et al. Isolated diastolic hypertension and target organ damage: Findings from the STANISLAS cohort. Clinical Cardiology. 2021;44(11):1516-25.
[4] Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity, kidney dysfunction and hypertension: mechanistic links. Nature reviews nephrology. 2019;15(6):367-85.
[5] Harshfield EL, Koulman A, Ziemek D, Marney L, Fauman EB, Paul DS, et al. An unbiased lipid phenotyping approach to study the genetic determinants of lipids and their association with coronary heart disease risk factors. Journal of Proteome Research. 2019;18(6):2397-410.
[6] Cartolano FD, Pappiani C, Freitas MC, Figueiredo Neto AM, Carioca AA, Damasceno NR. Is lipid accumulation product associated with an atherogenic lipoprotein profile in Brazilian subjects?. Arquivos brasileiros de cardiologia. 2018;110:339-47.
[7] Yang P, Kuc RE, Brame AL, Dyson A, Singer M, Glen RC, et al. [Pyr1] Apelin-13 (1–12) is a biologically active ACE2 metabolite of the endogenous cardiovascular peptide [Pyr1] Apelin-13. Frontiers in Neuroscience. 2017;11:92-8.
[8] Leung OM, Li J, Li X, Chan VW, Yang KY, Ku M, et al. Regulatory T cells promote apelin-mediated sprouting angiogenesis in type 2 diabetes. Cell reports. 2018;24(6):1610-26.
[9] O'Carroll AM, Lolait SJ, Harris LE, Pope GR. The apelin receptor APJ: journey from an orphan to a multifaceted regulator of homeostasis. Journal of Endocrinology. 2013;219(1):R13-35.
[10] Harrison DG. The mosaic theory revisited: common molecular mechanisms coordinating diverse organ and cellular events in hypertension. Journal of the American Society of Hypertension. 2013;7(1):68-74.
[11] Drummond GR, Vinh A, Guzik TJ, Sobey CG. Immune mechanisms of hypertension. Nature Reviews Immunology. 2019;19(8):517-32.
[12] Tsoupras A, Brummell C, Kealy C, Vitkaitis K, Redfern S, Zabetakis I. Cardio-protective properties and health benefits of fish lipid bioactives; the effects of thermal processing. Marine Drugs. 2022;20(3):187.
[13] Veturi Y, Lucas A, Bradford Y, Hui D, Dudek S, Theusch E, et al. A unified framework identifies new links between plasma lipids and diseases from electronic medical records across large-scale cohorts. Nature genetics. 2021;53(7):972-81.
[14] Shimizu Y, Kawashiri SY, Noguchi Y, Nagata Y, Maeda T, Hayashida N. Association between thyroid cysts and hypertension by atherosclerosis status: A cross-sectional study. Scientific Reports. 2021;11(1):1-9.
[15] Shimizu Y, Maeda T. Influence of height on endothelial maintenance activity: a narrative review. Environmental Health and Preventive Medicine. 2021;26(1):1-6.
[16] Xiang Q, Tian F, Xu J, Du X, Zhang S, Liu L. New insight into dyslipidemia‐induced cellular senescence in atherosclerosis. Biological Reviews. 2022;97(5):1844-67.
[17] Barnes GD, Alam S, Carter G, Pedersen CM, Lee KM, Hubbard TJ, et al. Sustained cardiovascular actions of APJ agonism during renin–angiotensin system activation and in patients with heart failure. Circulation: Heart Failure. 2013;6(3):482-91.
[18] Frump AL, Albrecht M, Yakubov B, Breuils-Bonnet S, Nadeau V, Tremblay E, et al. 17β-Estradiol and estrogen receptor α protect right ventricular function in pulmonary hypertension via BMPR2 and apelin. The Journal of Clinical Investigation. 2021;131(6):e129433.
[19] Li L, Zeng H, Chen JX. Apelin-13 increases myocardial progenitor cells and improves repair postmyocardial infarction. American Journal of Physiology-Heart and Circulatory Physiology. 2012;303(5):H605-18.
[20] Tempel D, de Boer M, van Deel ED, Haasdijk RA, Duncker DJ, Cheng C, et al. Apelin enhances cardiac neovascularization after myocardial infarction by recruiting aplnr+ circulating cells. Circulation research. 2012;111(5):585-98.
[21] Fukushima H, Kobayashi N, Takeshima H, Koguchi W, Ishimitsu T. Effects of olmesartan on Apelin/APJ and Akt/endothelial nitric oxide synthase pathway in Dahl rats with end-stage heart failure. Journal of cardiovascular pharmacology. 2010;55(1):83-8.
[22] Chapman FA, Nyimanu D, Maguire JJ, Davenport AP, Newby DE, Dhaun N. The therapeutic potential of apelin in kidney disease. Nature Reviews Nephrology. 2021;17(12):840-53.
[23] Sabry MM, Ramadan NM, Al Dreny BA, Rashed LA, Abo El Enein A. Protective effect of apelin preconditioning in a rat model of hepatic ischemia reperfusion injury; possible interaction between the apelin/APJ system, Ang II/AT1R system and eNOS. United European Gastroenterology Journal. 2019;7(5):689-98.
[24] Zhang J, Lin X, Xu J, Tang F. Apelin-13 reduces oxidative stress induced by uric acid via downregulation of renin-angiotensin system in adipose tissue. Toxicology Letters. 2019;305:51-7.
[25] Girault-Sotias PE, Gerbier R, Flahault A, de Mota N, Llorens-Cortes C. Apelin and vasopressin: the yin and yang of water balance. Frontiers in Endocrinology. 2021;12:735515.
[26] Rozwadowski J, Borodzicz-Jażdżyk S, Czarzasta K, Cudnoch-Jędrzejewska A. A Review of the Roles of Apelin and ELABELA Peptide Ligands in Cardiovascular Disease, Including Heart Failure and Hypertension. Medical Science Monitor. 2022;28.
[27] Li C, Cheng H, Adhikari BK, Wang S, Yang N, Liu W, et al. The Role of Apelin–APJ System in Diabetes and Obesity. Frontiers in Endocrinology. 2022;13.